Fig. 2From: Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case reportPre- and post-treatment MRI findings showing near complete response to combination therapy with pembrolizumab and tocilizumab. Notably, the patient initially had 18 intracranial metastases that were completely resolvedBack to article page